MAM
Cairn India signs multi-million rupee deal with Hockey India
MUMBAI: Cairn India, the world’s leading energy company, has signed a multi-million rupee deal with Hockey India (HI) to co-sponsor India‘s national hockey teams for a tenure of three years.
This association will cover the senior and junior national men and women teams. The financial details of the deal were not disclosed.
The senior Indian Men and Women Hockey teams will be seen sporting the Cairn logo for the first time when they will take part in the Hero Hockey World League Round 2 tournaments to be held at Major Dhyan Chand National Stadium, New Delhi from 18-24 February.
Cairn has decided to join forces with the national game of the country and plans through several initiatives to encourage the sport amongst the new generation.
HI Secretary General Dr Narinder Batra said, “We welcome Cairn for joining Hockey India and being part of the journey to revive hockey in the country. This association will further boost the game and help the sport reach new levels. Hockey India thanks Cairn India for coming on board to become our partner in this exciting journey.”
Cairn India Head Corporate Affairs & Communications Dr Sunil Bharati said, “Hockey is our national game and we are proud to be associated with this energetic game. The partnership and the journey ahead will indeed be a privileged one for the entire Cairn family.
“It is the first big step for us towards nurturing and growing this sport, both on a national stage as well as the international arena. Cairn India’s decision to associate with Hockey also aims at fuelling the resurgent interest in the national sports amongst youngsters.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
